Brainstorm Health: Sage Postpartum Drug, Gilead Price Hikes, Peloton Suit [Fortune]
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: Fortune
Brainstorm Health: Sage Postpartum Drug, Gilead Price Hikes, Peloton Suit By Sy Mukherjee 6:49 PM EDT Hello and happy hump day, readers. Sage Therapeutics notched a pioneering victory on Tuesday when the Food and Drug Administration (FDA) approved its postpartum depression drug Zulresso The agency’s approval of Zulresso, the brand name for a therapy called brexanolone, was widely expected In fact, as the FDA explains, the drug’s marketing comes with a number of restrictions. “Because of concerns about serious risks, including excessive sedation or sudden loss of consciousness during administration, Zulresso has been approved with a Risk Evaluation and Mitigation Strategy (REMS) and is only available to patients through a restricted distribution program at certified health care facilities where the health care provider can carefully monitor the patient,” wrote the FDA’s Tiffany Farchione in a statement. Zulresso must be administered via IV infusion by a doctor at a health care facility
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target raised by analysts at JPMorgan Chase & Co. from $24.00 to $29.00. They now have an "overweight" rating on the stock.MarketBeat
- Why Is Sage Therapeutics, Inc. (SAGE) Down 22% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target raised by analysts at Morgan Stanley from $20.00 to $22.00. They now have an "equal weight" rating on the stock.MarketBeat
- Sage Therapeutics to Present at Upcoming March Investor ConferencesBusiness Wire
- Huntington's Disease Treatment Market Size to Worth USD 1,217.10 Million by 2032 [Yahoo! Finance]Yahoo! Finance
SAGE
Earnings
- 2/14/24 - Beat
SAGE
Sec Filings
- 3/27/24 - Form SC
- 3/26/24 - Form 8-K
- 2/21/24 - Form SC
- SAGE's page on the SEC website